

SUPPLEMENTARY MATERIAL FOR

**Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine:
A Post-Hoc Analysis of Two Randomized Controlled Studies**

Matt Fisher, PharmD¹; Abhay Aher, MS¹;

Mako Araga, MS¹; Billy Franks, PhD²

¹Haleon, Warren, NJ


²GlaxoSmithKline Consumer Healthcare B.V., Amersfoort, Netherlands

Corresponding Author

Matt Fisher, PharmD

matthew.j.fisher@haleon.com

Supplementary Material. Patient disposition.



*A dose preference was expressed by 258 patients, but complete baseline data were missing for 36 patients.